Metronomic cyclophosphamide: An alternative treatment for hepatic epithelioid hemangioendothelioma

Journal of Hepatology

Volumn 58, Issue 6, 2013, Pages 1254-1257

  Lakkis, Zaher ^a   Kim, Stefano ^a   Delabrousse, Eric ^a   Jary, Marine ^a,b   Nguyen, Thierry ^a   Mantion, Georges ^a   Heyd, Bruno ^a   Lassabe, Catherine ^c   Borg, Christophe ^a,b  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b INSERM   (France)

^c University of Belfort   (France)

Author keywords

Anti angiogenic; Cyclophosphamide; Endothelial cells; Epithelioid tumor; Hemangioendothelioma; Metronomic chemotherapy

Indexed keywords

BEVACIZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; OPIATE; PAMIDRONIC ACID; ALKYLATING AGENT;

ADULT; ANTIANGIOGENIC THERAPY; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEMANGIOENDOTHELIOMA; HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA; HUMAN; LIVER BIOPSY; LIVER TUMOR; MALE; METRONOMIC DRUG ADMINISTRATION; PANCYTOPENIA; PATIENT REFERRAL; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; HEMANGIOENDOTHELIOMA, EPITHELIOID; LIVER NEOPLASMS; MIDDLE AGED;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; FEMALE; HEMANGIOENDOTHELIOMA, EPITHELIOID; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 84877922256     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.01.043     Document Type: Article

References (34)

1. S.W. Weiss, and F.M. Enzinger Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma Cancer 50 1982 970 981
2. H.R. Makhlouf, K.G. Ishak, and Z.D. Goodman Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases Cancer 85 1999 562 582
3. G. Bocci, K.C. Nicolaou, and R.S. Kerbel Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective anti-angiogenic window for various chemotherapeutic drugs Cancer Res 62 2002 6938 6943
4. A. Mehrabi, A. Kashfi, H. Fonouni, P. Schemmer, B.M. Schmied, and P. Hallscheidt Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy Cancer 107 2006 2108 2121
5. D.T. Kehagias, L.A. Moulopoulos, A. Antoniou, V. Psychogios, A. Vourtsi, and L.J. Vlahos Hepatic epithelioid hemangioendothelioma: MR imaging findings Hepatogastroenterology 47 2000 1711 1713
6. A.I. Alomari The lollipop sign: a new cross-sectional sign of hepatic epithelioid hemangioendothelioma Eur J Radiol 59 2006 460 464
7. B.D. Nguyen Epithelioid hemangioendothelioma of the liver with F-18 FDG PET imaging Clin Nucl Med 29 2004 828 830
8. K. Uchimura, M. Nakamuta, M. Osoegawa, S. Takeaki, H. Nishi, and H. Iwamoto Hepatic epithelioid hemangioendothelioma J Clin Gastroenterol 32 2001 431 434
9. L. Mosoia, J.Y. Mabrut, M. Adham, O. Boillot, C. Ducerf, and C. Partensky Hepatic epithelioid hemangioendothelioma: long-term results of surgical management J Surg Oncol 98 2008 432 437
10. J.P. Lerut, G. Orlando, R. Adam, M. Schiavo, J. Klempnauer, and D. Mirza The place of liver transplantation in the treatment of hepatic epitheloid hemangioendothelioma: report of the European liver transplant registry Ann Surg 246 2007 949 957
11. J.A. Emamaullee, R. Edgar, C. Toso, A. Thiesen, V. Bain, and D. Bigam Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: implications for treatment and surgical management Liver Transpl 16 2010 191 197
12. R.C. Mascarenhas, A.N. Sanghvi, L. Friedlander, S.J. Geyer, H.S. Beasley, and D.H. Van Thiel Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma Oncology 67 2004 471 475
13. L. Calabrò, A.M. Di Giacomo, M. Altomonte, E. Fonsatti, M.A. Mazzei, and L. Volterrani Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? J Exp Clin Cancer Res 26 2007 145 150
14. F.H. Galvão, A. Bakonyi-Neto, M.A. Machado, A.Q. Farias, E.S. Mello, and M.E. Diz Interferon alpha-2B and liver resection to treat multifocal hepatic epithelioid hemangioendothelioma: a relevant approach to avoid liver transplantation Transplant Proc 37 2005 4354 4358
15. L.K. Kayler, R.M. Merion, J.D. Arenas, J.C. Magee, D.A. Campbell, and S.M. Rudich Epithelioid hemangioendothelioma of the liver disseminated to the peritoneum treated with liver transplantation and interferon alpha-2B Transplantation 74 2002 128 130
16. M.D. Vignon-Pennamen, M. Rybojad, O. Verola, A. Puissant, and P. Morel Epithelioid hemangioendothelioma: disease course in 3 cases Ann Dermatol Venereol 124 1997 165 166
17. A. Kassam, and K. Mandel Metastatic hepatic epithelioid hemangioendothelioma in a teenage girl J Pediatr Hematol Oncol 30 2008 550 552
18. B. Sangro, M. Iñarrairaegui, and N. Fernández-Ros Malignant epithelioid hemangioendothelioma of the liver successfully treated with Sorafenib Rare Tumors 4 2012 e34
19. L. Belmont, L. Zemoura, and L.J. Couderc Pulmonary epithelioid haemangioendothelioma and bevacizumab J Thorac Oncol 3 2008 557 558
20. K. Trautmann, A. Bethke, G. Ehninger, and G. Folprecht Bevacizumab for recurrent hemangioendothelioma Acta Oncol 50 2011 153 154
21. M.E. Lutsiak, R.T. Semnani, R. De Pascalis, S.V. Kashmiri, J. Schlom, and H. Sabzevari Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood 105 2005 2862 2868
22. N. Penel, A. Adenis, and G. Bocci Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? Crit Rev Oncol Hematol 82 2012 40 50
23. S. Man, G. Bocci, G. Francia, S.K. Green, S. Jothy, and D. Hanahan Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water Cancer Res 62 2002 2731 2735
24. R.S. Kerbel, and B.A. Kamen The anti-angiogenic basis of metronomic chemotherapy Nature 4 2004 423 436
25. D. Hanahan, G. Bergers, and E. Bergsland Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice J Clin Invest 105 2000 1045
26. F. Bertolini, S. Paul, P. Mancuso, S. Monestiroli, and A. Gobbi Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells Cancer Res 63 2003 4342 4346
27. Y. Hamano, H. Sugimoto, M.A. Soubasakos, M. Kieran, B.R. Olsen, and J. Lawler Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression Cancer Res 64 2004 1570
28. J.E. Damber, C. Vallbo, P. Albertsson, B. Lennernas, and K. Norrby The anti-tumor effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin Cancer Chemother Pharmacol 58 2006 354 360
29. M. Colleoni, A. Rocca, and M.T. Sandri Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels Ann Oncol 13 2002 73 80
30. L. Orlando, A. Cardillo, and A. Rocca Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer Anticancer Drugs 17 2006 961 967
31. G. Bocci, M. Tuccori, U. Emmenegger, V. Liguori, A. Falcone, and R.S. Kerbel Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation Ann Oncol 16 2005 1243 1252
32. D. Raghavan, K. Cox, and B.S. Pearson Oral cyclophosphamide for the management of hormone-refractory prostate cancer Br J Urol 72 1993 625 628
33. R. Lord, S. Nair, A. Schache, J. Spicer, N. Somaihah, and V. Khoo Low Dose Metronomic Oral Cyclophosphamide for Hormone Resistant Prostate Cancer: A Phase II Study J Urology 177 2007 2136 2140
34. O. Mir, J. Domont, A. Cioffi, S. Bonvalot, B. Boulet, and C. Le Pechoux Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma Eur J Cancer 47 2011 515 519